1Fekadu, A, Donocik, JG, Cleare, AJ. Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry 2018; 18: 100.
2Fekadu, A, Wooderson, SC, Markopoulo, K, Donaldson, C, Papadopoulos, A, Cleare, AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord 2009; 116: 4–11.
3Zhou, X, Ravindran, AV, Qin, B, Del Giovane, C, Li, Q, Bauer, M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015; 76: E487–98.
4Bandelow, B, Reitt, M, Röver, C, Michaelis, S, Görlich, Y, Wedekind, D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015; 30: 183–92.
5Strawbridge, R, Carter, B, Marwood, L, Taylor, R, Mantingh, T, Nikolova, V, et al. Efficacy of Psychological and Pharmacological Augmentation Therapies for Treatment-Resistant Depression: A Systematic Review and Meta-analysis. PROSPERO: The International Prospective Register of Systematic Reviews, 2018. Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018088009.
6Conway, CR, George, MS, Sackeim, HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry 2017; 74: 9–10.
7National Institute for Health and Clinical Excellence (NICE). Depression in Adults: Treatment and Management. NICE (UK), 2017.
8Scottish Intercollegiate Guidelines Network (SIGN). Methodology Checklist 2: Controlled Trials. 2012. Available from: http://www.sign.ac.uk. 9Higgins, J, Green, S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
10Cuijpers, P, Weitz, E, Cristea, IA, Twisk, J. Pre-post effect sizes should be avoided in meta-analyses. Epidemiol Psychiatr Sci 2017; 26: 364–8.
11Su, T-P, Chen, M-H, Li, C-T, Lin, W-C, Hong, C-J, Gueorguieva, R, et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharm 2017; 42: 2482–92.
12Fonagy, P, Rost, F, Carlyle, J-A, Mcpherson, S, Thomas, R, Fearon, RMP, et al. Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS). World Psychiatry 2015; 14: 312–21.
13Yoshimura, R, Kishi, T, Hori, H, Ikenouchi-Sugita, A, Katsuki, A, Umene-Nakano, W, et al. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 355–7.
14McAllister-Williams, RH, Anderson, IM, Finkelmeyer, A, Gallagher, P, Grunze, HCR, Haddad, PM, et al. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry 2016; 3: 117–27.
15Girlanda, F, Cipriani, A, Agrimi, E, Appino, MG, Barichello, A, Beneduce, R, et al. Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial. BMC Res Notes 2014; 7: 731.
16Heresco-Levy, U, Gelfin, G, Bloch, B, Levin, R, Edelman, S, Javitt, DC, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013; 16: 501–6.
17Husain M, I, Chaudhry, IB, Husain, N, Khoso, AB, Rahman, RR, Hamirani, MM, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol (Oxf) 2017; 31: 1166–75.
18Eisendrath, SJ, Gillung, E, Delucchi, KL, Segal, ZV, Nelson, JC, McInnes, LA, et al. A randomized controlled trial of mindfulness-based cognitive therapy for treatment-resistant depression. Psychother Psychosom 2016; 85: 99–110.
19Fang, Y, Yuan, C, Xu, Y, Chen, J, Wu, Z, Cao, L, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol 2011; 31: 638–42.
20Nierenberg, A, Papakostas, G, Petersen, T, Montoya, H, Worthington, J, Tedlow, J, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003; 23: 92–5.
21Santos, MA, Rocha, FL, Hara, C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry 2008; 10: 187–90.
22Thase, ME, Youakim, JM, Skuban, A, Hobart, M, Augustine, C, Zhang, P, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76: 1224–31.
23Thase, ME, Youakim, JM, Skuban, A, Hobart, M, Zhang, P, McQuade, RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015; 76: 1232–40.
24Baumann, P, Nil, R, Souche, A, Montaldi, S, Baettig, D, Lambert, S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307–14.
25Hauksson, P, Ingibergsdottir, S, Gunnarsdottir, T, Jonsdottir, IH. Effectiveness of cognitive behaviour therapy for treatment-resistant depression with psychiatric comorbidity: comparison of individual versus group CBT in an interdisciplinary rehabilitation setting. Nord J Psychiatry 2017; 71: 465–72.
26Dunner, DL, Amsterdam, JD, Shelton, RC, Loebel, A, Romano, SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry. 2007; 68: 1071–7.
27Barbee, JG, Thompson, TR, Jamhour, NJ, Stewart, JW, Conrad, EJ, Reimherr, FW, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72: 1405–12.
28Bauer, M, Dell'Osso, L, Kasper, S, Pitchot, W, Vansvik, ED, Koehler, J, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord 2013; 151: 209–19.
29Berman, RM, Marcus, RN, Swanink, R, McQuade, RD, Carson, WH, Corey-Lisle, PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843–53.
30Berman, RM, Fava, M, Thase, ME, Trivedi, MH, Swanink, R, McQuade, RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197–206.
31Maes, M, Vandoolaeghe, E, Desnyder, R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996; 41: 201–10.
32Marcus, RN, McQuade, RD, Carson, WH, Hennicken, D, Fava, M, Simon, JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 156–65.
33Moller, H-J, Demyttenaere, K, Olausson, B, Szamosi, J, Wilson, E, Hosford, D, et al. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry 2015; 16: 483–501.
34Ozaki, N, Otsubo, T, Kato, M, Higuchi, T, Ono, H, Kamijima, K. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. Psychiatry Clin Neurosci 2015; 69: 34–42.
35Shelton, RC, Tollefson, GD, Tohen, M, Stahl, S, Gannon, KS, Jacobs, TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–4.
36Nierenberg, AA, Fava, M, Trivedi, MH, Wisniewski, SR, Thase, ME, McGrath, PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1519–30, quiz 1665.
37Patkar, AA, Masand, PS, Pae, C-U, Peindl, K, Hooper-Wood, C, Mannelli, P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006; 26: 653–6.
38Schindler, F, Anghelescu, IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol 2007; 22: 179–82.
39Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet 2018; 391: 1357–66.
40Papadimitropoulou, K, Vossen, C, Karabis, A, Donatti, C, Kubitz, N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin 2017; 33: 701–11.
41Bauer, M, Pfennig, A, Severus, E, Whybrow, PC, Angst, J, Möller, H-J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013; 14: 334–85.
42Amick, HR, Gartlehner, G, Gaynes, BN, Forneris, C, Asher, GN, Morgan, LC, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015; 351: h6019.
43McPherson, S, Cairns, P, Carlyle, J, Shapiro, DA, Richardson, P, Taylor, D. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 2005; 111: 331–40.
44Holmes, EA, Ghaderi, A, Harmer, CJ, Ramchandani, PG, Cuijpers, P, Morrison, AP, et al. The Lancet Psychiatry Commission on psychological treatments research in tomorrow's science. Lancet Psychiatry 2018; 5: 237–86.
45Wiles, N, Thomas, L, Abel, A, Ridgway, N, Turner, N, Campbell, J, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013; 381: 375–84.
46Cleare, A, Pariante, CM, Young, AH, Anderson, IM, Christmas, D, Cowen, PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol Oxf Engl 2015; 29: 459–525.